Fragility and Plasticity of CCR8+Tregs: Providing New Directions for Cancer Treatment
DOI:
https://doi.org/10.54097/1aye9c25Keywords:
Regulatory T cells (Tregs); CCR8; fragility; plasticity; tumor immunotherapy.Abstract
Regulatory T cells (Tregs) are crucial for maintaining immune homeostasis. However, in the tumor microenvironment, tumor cells induce Tregs to exert immunosuppressive effects, leading to the failure of anti-tumor immunity. Traditional Treg clearance strategies, due to their lack of selectivity, damage peripheral normal Tregs during treatment, causing severe autoimmune side effects. This article analyzes the biological characteristics, fragility, and plasticity of CCR8+Tregs and their molecular mechanisms. The results show that CCR8+Tregs are specifically highly expressed on tumor-infiltrating Tregs, and after binding to the C-C Motif Chemokine Ligand 1 (CCL1), they maintain the stability of the Foxp3 transcriptional complex through the PI3K/AKT signaling axis. Blocking CCR8 signaling can trigger FOXO1 nuclear export and inhibit c-MAF expression, inducing IFN-γ-dependent fragility in Tregs. This fragility is the molecular basis of its functional plasticity, which can drive Tregs to reprogram to a Th1-like pro-inflammatory phenotype, thereby reshaping the TME from inhibition to activation. In summary, targeting the fragility and plasticity of CCR8+Tregs holds promise for achieving precise immune regulation, providing new insights for optimizing combined immunotherapy for tumors.
Downloads
References
[1] Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, et al. CCR8+FOXp3+ Treg cells as master drivers of immune regulation. Proc Natl Acad Sci U S A. 2017, 114(23): 6086–91.
[2] Navarrete M, Costoya C, Galvez-Cancino F, Peggs KS, Marabelle A, Quezada SA. Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development. Annu Rev Med. 2026, 77(1): 239–51.
[3] Kim N, Kim MH, Pyo J, Lee SM, Jang JS, Lee DW, et al. CCR8 as a Therapeutic Novel Target: Omics-Integrated Comprehensive Analysis for Systematically Prioritizing Indications. Biomedicines. 2023, 11(11): 2910.
[4] Wang T, Zhou Q, Zeng H, Zhang H, Liu Z, Shao J, et al. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2020, 69(9): 1855–67.
[5] Fujikawa M, Koma YI, Hosono M, Urakawa N, Tanigawa K, Shimizu M, et al. Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway. Am J Pathol. 2021, 191(4): 686–703.
[6] Liu J, Zhang B, Zhang G, Shang D. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point? Front Immunol. 2024, 15: 1345838.
[7] Chen Q, Shen M, Yan M, Han X, Mu S, Li Y, et al. Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer. J Transl Med. 2024, 22: 709.
[8] Overacre-Delgoffe AE, Vignali DAA. TREG FRAGILITY: A PREREQUISITE FOR EFFECTIVE ANTITUMOR IMMUNITY? Cancer Immunol Res. 2018, 6(8): 882–7.
[9] Tian B, Wang Z, Cao M, Wang N, Jia X, Zhang Y, et al. CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype. J Exp Clin Cancer Res. 2025, 44: 113.
[10] Ortega-Mejia II, Romero-López N, Casasola-Vargas JC, Burgos-Vargas R, Domínguez-López ML, Romero-López JP. Treg cell plasticity as a driver of inflammation in spondyloarthritis and psoriasis. Front Immunol. 2025, 16: 1621396.
[11] Shi H, Chi H. Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity. Front Immunol. 2019, 10: 2716.
[12] Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021, 7(24): eabi5781.
[13] Roider HG, Hoff S, Tseng SY, Berndt S, Trautwein M, Filarsky K, et al. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clin Exp Med. 2024, 24(1): 122.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

